thalidomide and hydroxyurea
Phase 2Small molecule
thalidomide and hydroxyurea is one of 17 small molecule programs targeting Beta-Thalassemia. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Beta-Thalassemia
#DrugCompanyPhaseTrials
1Exjade
NovartisApproved
Thalomid
Bristol-Myers SquibbApproved
Desferal
Jazz PharmaceuticalsApproved
Droxia
TTheravia
Approved
Glucophage
EMD SeronoApproved
Viagra
VViatris Specialty LLC
Approved
Ferriprox
Chiesi Farmaceutici S.p.A.Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
CTX001
Vertex PharmaceuticalsPhase 3
ACE-536
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Beta-Thalassemia1 trial
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
Active, not recruiting·NNational Institute of Blood and Marrow Transplant (NIBMT), Pakistan·Phase 2·NCT06490601·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for thalidomide and hydroxyurea. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details